Oxygen Atom Of The Saccharide Radical Is Bonded To A Cyclohexyl Radical (e.g., Kasugamycin, Etc.) Patents (Class 435/79)
-
Patent number: 5994149Abstract: A slide having a portion thereof provided with transparent adhesive which adheres to a test sample. The slide and adhesive may be transparent. Specific types of infection and particularly fungal infections can be detected in the test sample using immunotest-methods. In a special embodiment the adhesive slide is fashioned with a peripheral lip or well to contain a test sample and a reagent.Type: GrantFiled: October 1, 1997Date of Patent: November 30, 1999Assignee: Leonard BloomInventors: Howard N. Robinson, Francisco Tausk, Bruce Bochner, Neil F. Martin
-
Patent number: 5989842Abstract: The invention is a method for the enzymatic labeling of biomolecules, such as immunoglobulin, peptide, hormone, or hapten, which involves oxidizing horseradishperoxidase (HRP) with a periodate, crosslinking the oxidized HRP with an .alpha.,.OMEGA.-diaminoalkane, and coupling the biomolecule with the crosslinked, oxidized HRP.Type: GrantFiled: June 26, 1998Date of Patent: November 23, 1999Assignee: Bio-Tez Berlin-Buch GmbHInventors: Eberhard Schmidt, Christa Weiss
-
Patent number: 5990160Abstract: The present invention concerns the use of puberulic or puberulonic acid as inhibitors of the enzyme iositol monophosphatase (EC 3.1.3.25) and thus useful in the treatment of manic or depressive symptoms.Type: GrantFiled: May 14, 1999Date of Patent: November 23, 1999Assignee: Gruppo Lepetit, SpAInventors: Khalid Islam, Stefania Stefanelli, Federica Sponga, Maurizio Denaro
-
Patent number: 5985590Abstract: CrFC21 cDNA was cloned into two mammalian vectors: pCIneo and pCDNAI, both of which carry the strong CMV promoter for expression in mammalian cell lines. Various CrFC cDNA constructs transformed into P. pastoris and S. cerevisiae were expressed to yield full-length recombinant Factor C (rCrFC) protein of .about.130 kDa which is immunoreactive. The rCrFC is expressed in an intracellular, insoluble form. Intracellular localization of the nascent protein provides protection from premature digestion by proteases secreted by the host cell. Subsequent to its synthesis, rCrFC is solubilized and purified under pyrogen-free conditions. Using established protocols, the protein can be denatured and renatured to recover its biological functionality. By manipulation of the 5' end of CrFC26, truncated constructs containing this cDNA are expressed by S. cerevisiae to give immunoreactive rCrFC. The rCrFC produced from both CrFC21 and CrFC26 constructs, solubilized by Triton X-100 or SDS, is found to be immunoreactive.Type: GrantFiled: June 18, 1997Date of Patent: November 16, 1999Assignee: National University of SingaporeInventors: Jeak Ling Ding, Bow Ho
-
Patent number: 5985545Abstract: HIV- virus-infected cells secrete .alpha.-N-acetylgalactosaminidase into the blood stream, resulting in the deglycosylation of the Gc protein. This inactivates the MAF precursor activity of the Gc protein, leading to immunosuppression. Thus, the .alpha.-N-acetylgalactosaminidase activity in a patient's bloodstream can serve as a diagnostic and prognostic index. Antibody-sandwich ELISA method and kits for HIV virus specific .alpha.-N-acetylgalactosaminidase as an antigen were developed to detect serum or plasma .alpha.-N-acetylgalactosaminidase activity in AIDS/HIV-infected patients and are used as a diagnostic/prognostic index.Type: GrantFiled: March 13, 1998Date of Patent: November 16, 1999Inventor: Nobuto Yamamoto
-
Patent number: 5985548Abstract: A method for the amplified detection of an analyte, wherein amplification is achieved by replication of a target nucleic acid sequence which has been immobilized in response to analyte.Type: GrantFiled: February 13, 1995Date of Patent: November 16, 1999Assignee: E. I. du Pont de Nemours and CompanyInventors: David Nash Collier, Richard Calvin Ebersole, Tina Marie Hatfield, Edwin R. Hendrickson, John Richard Moran
-
Patent number: 5981202Abstract: A method for assaying a substance is provided in which an optical image is obtained from spots of light emitted from a chemiluminescent material capable of undergoing a luminescent reaction. The method comprises: (a) a step of distributing solid particles on the surface of a support, the solid particles having a diameter of not more than 100 .mu.Type: GrantFiled: March 3, 1995Date of Patent: November 9, 1999Assignee: Biosensor Laboratories Co., Ltd.Inventor: Masayuki Masuko
-
Patent number: 5981203Abstract: An enzyme sandwich immunoassay, device and cassette therefor for determining a target analyte are described. The enzyme sandwich immunoassay cassette (B) comprises a microporous membrane support (m) having coated thereon a conductive metal layer overlaid with a capture antibody layer (e).Type: GrantFiled: January 13, 1997Date of Patent: November 9, 1999Assignee: The Regents of the University of MichiganInventors: Mark E. Meyerhoff, Chuanming Duan
-
Patent number: 5981204Abstract: A method and a buffer solution are set forth for testing for cannabinoid analytes extracted form a hair sample using enzyme linked immunosorbant assay (ELISA). The method includes preparation of a hair extract cocktail using an inorganic base and aliphatic alcohol and thereafter adding the buffer according to the present invention including at least one of (a) a phosphate buffer, (b) proteinaceous substance, (c) a non-ionic surfactant and (d) a polyhydric alcohol. The buffered solution is evaporated and analyzed using ELISA. By using ELISA to determine clearly negative samples, expensive confirmatory testing can be reserved for only those samples determined to be not clearly negative.Type: GrantFiled: May 6, 1997Date of Patent: November 9, 1999Inventors: Ted Donald Johnson, W. Craig Brown, Raymond C. Kelly
-
Patent number: 5976818Abstract: Hybridomally produced monoclonal antibodies specifically immunoreactive with the glycoprotein carrying the CA 125 epitope. Monoclonal antibodies recognize both high and low molecular weight subunits of the antigen, and identify the antigen in the cytoplasm and the extracellular matrix of CA 125 producing cells. An immunoassay for the detection of CA 125 utilizing the monoclonal antibodies is described.Type: GrantFiled: April 2, 1996Date of Patent: November 2, 1999Assignee: The Board of Trustees of The University of ArkansasInventor: Timothy J. O'Brien
-
Patent number: 5976785Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.Type: GrantFiled: December 20, 1991Date of Patent: November 2, 1999Assignee: Institut PasteurInventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
-
Patent number: 5976811Abstract: Antibodies for the selective immunological determination of bile acids in biological matricesPolyclonal antibodies for the selective immunological determination of bile acids in biological matrices, a process for the preparation of these antibodies, and their use in immunoassays are described.Type: GrantFiled: February 28, 1997Date of Patent: November 2, 1999Assignee: Hoescht AktiengesellschaftInventors: Stefan Mullner, Axel Hoffmann
-
Patent number: 5972625Abstract: The present invention provides novel assays for determining the ability of a test compound to inhibit intercellular adhesion mediated by a selectin receptor, such as the LHR. The assay involves coating a surface of a solid substrate with an antibody which specifically binds a selectin ligand. Preferred are antibodies against GlyCAM-1 which is a natural biological ligand for L-Selectin and also binds to P-Selectin and E-Selectin. A compound such as GlyCAM-1 is then bound to the antibodies. The test compound mixture putatively containing a selectin ligand is then brought into contact with a chimeric molecule. The test mixture might include any compound which might block or hinder binding between a selectin receptor and the ligand bound to the antibody.Type: GrantFiled: July 2, 1997Date of Patent: October 26, 1999Assignee: The Regents of the University of CaliforniaInventors: Steven D. Rosen, Mark Singer, Yasuyuki Imai
-
Patent number: 5972634Abstract: The disclosed invention relates to assays for detecting and quantifying A.beta. peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of A.beta. peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of A.beta. peptides from biological fluids are taught.Type: GrantFiled: August 4, 1997Date of Patent: October 26, 1999Assignee: The General Hospital CorporationInventors: Rudolph E. Tanzi, Ashley I. Bush, Robert D. Moir
-
Patent number: 5973123Abstract: The subject matter of the present invention are high-affinity monoclonal antibodies against MIA (Melanoma inhibitory activity) in native conformation, which can be used for the detection of malignant melanomas, their use for the detection of MIA as well as immunoassays for the detection of MIA.Type: GrantFiled: December 18, 1997Date of Patent: October 26, 1999Assignee: Roche Diagnostics GmbHInventors: Brigitte Kaluza, Iise Bartke, Helmut Lenz, Martin Kaufmann, Reinhard Buttner, Anja-Katrin Bosserhoff
-
Patent number: 5972631Abstract: A method is described for the rapid, sensitive and accurate determination of sucrose in biological fluids. A substrate is pre-coated with a glucose or fructose polymer and a transglycosidase enzyme. When the coated substrate is incubated with biological fluids containing concentrations of sucrose, the transglycosidase enzyme transfers monomers of glucose or fructose from the sucrose to the glucose or fructose polymer. The dimensions of the polymer are increased in proportion to the sucrose concentration of the samples. Newly formed polymer is subsequently quantitated in an immunoassay which employs either a combination of a carbohydrate-binding protein (which may be an antibody) and a conjugate of a secondary antibody and a marker enzyme, or a conjugate of a carbohydrate-binding protein and a marker enzyme. The assay is accurate at sucrose concentrations below 1 .mu.g/mL. No interference was observed at glucose concentrations as high as 25 mM.Type: GrantFiled: November 3, 1997Date of Patent: October 26, 1999Assignee: De Novo Enzyme CorporationInventors: Thor Jon Borgford, Kathleen Iris Racher, Curtis Archie John Braun
-
Patent number: 5972633Abstract: The present invention relates to antibodies against heart muscle actin, processes for the production of such antibodies and their use.Type: GrantFiled: January 14, 1998Date of Patent: October 26, 1999Assignee: Progen Biotechnik GmbHInventors: Werner Wilhelm Franke, Sabine Stumpp, Sabine Stehr
-
Patent number: 5972336Abstract: Method of eliciting in a mammalian host a protective immune response to Helicobacter infection by administering to the host an immunogenically effective amount of a Helicobacter urease or urease subunits as antigen. Vaccine compositions are also provided.Type: GrantFiled: July 6, 1993Date of Patent: October 26, 1999Assignee: OraVax Merieux Co.Inventors: Pierre Michetti, Andre Blum, Catherine Davin, Rainer Haas, Irene Corthesy-Theulaz, Jean-Pierre Kraehenbuhl, Emilia Saraga
-
Patent number: 5972717Abstract: A method of detecting heparin-induced antibodies to complete a diagnosis of heparin-induced thrombocytopenia (HITP) is disclosed. This method comprises the first step of attaching a glycosaminoglycan to a solid support, wherein the glycosaminoglycan is attached to the solid support only at the reducing end of the molecule (unidirectionally). Platelet factor 4 is then bound to the glycosaminoglycan forming a complex having an epitope recognizable by antibodies generated in an HITP immune response. Human blood plasma or serum from a patient suspected of having HITP is exposed to the complex and the complex is analyzed to determine if HITP-related antibodies are present. A device and kit used in performing the diagnostic assay are also disclosed.Type: GrantFiled: November 19, 1997Date of Patent: October 26, 1999Assignee: The Blood Center Research Foundation, Inc.Inventors: Richard H. Aster, Gian Visentin
-
Patent number: 5968758Abstract: Antibodies having binding affinity for free IGFBP-1, biological compositions including antibodies having binding affinity for free IGFBP-1, kits for detecting free IGFBP-1 using the antibodies, and cell lines for producing the antibodies are provided. Also provided are devices and methods for detecting free IGFBP-1 and a rupture in a fetal membrane based on the presence of amniotic fluid in a vaginal secretion, as indicated by the presence of free IGFBP-1 in the vaginal secretion. The antibodies that are provided may be characterized by their ability to selectively recognize those IGFBP-1 molecules which are free of IGF-1 and IGF-2, i.e., antibodies which have a binding affinity for free IGFBP-1 that is greater than a binding affinity of the antibody to bound IGFBP-1. These antibodies may also be characterized by their competition with IGF-1 and IGF-2 for binding to IGFBP-1.Type: GrantFiled: October 28, 1996Date of Patent: October 19, 1999Assignee: California Research LLCInventors: Boris Fuks, Marina Boltovskaya, Alexander Konstantinov, Svetlana Nazimova, Nelli Starosvetskaya, Alexander Stepanov, Evgeny Zaraisky
-
Patent number: 5965378Abstract: The invention concerns a composition composed of several different antibodies or/and antibody fragments which is suitable as a reagent to reduce interferences in an immunological method for the class-specific detection of antibodies from one or several of the immunoglobulin classes G, M, A, D and E.Type: GrantFiled: April 24, 1997Date of Patent: October 12, 1999Assignee: Roche Diagnostics GmbHInventors: Dittmar Schlieper, Helmut Lenz, Urban Schmitt, Volker Klemt
-
Patent number: 5965457Abstract: Compounds and methods are provided for use in purification of CD34.sup.+ cells and specific surface antigens thereof. The present invention discloses methods for releasing CD34.sup.+ cells, as well as compounds having a carbohydrate epitope of the CD34 surface antigen, from an affinity matrix, using carbohydrates having the structure:Neu5Ac.alpha.2-3Gal.beta.1-4(X)wherein (X) is GlcNAc, or a monosaccharide or a cyclohexane derivative that is structurally similar to GlcNAc.Type: GrantFiled: June 6, 1995Date of Patent: October 12, 1999Inventor: John L. Magnani
-
Patent number: 5965131Abstract: An improvement in in vivo pretargeting methods for delivering diagnostic or therapeutic agents to a target site in a mammal uses a clearing agent that binds to the target-binding site of the targeting species, whereby non-bound primary targeting species is cleared from circulation but the clearing agent does not remove the bound primary targeting species. Anti-idiotype antibodies and antibody fragments are preferred clearing agents. Fast clearance is achieved by glycosylating the clearing agent with sugar residues that bind to the hepatic asialoglycoprotein receptor.Type: GrantFiled: October 9, 1996Date of Patent: October 12, 1999Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, Serengulam V. Govindan, Habibe Karacay
-
Patent number: 5965356Abstract: A recombinant virus (ICP10.DELTA.RR) has been developed which is useful in a Western blot assay to specifically detect antibody to HSV-2, even the presence of co-existing antibody to HSV-1.Type: GrantFiled: January 29, 1998Date of Patent: October 12, 1999Assignee: University of Maryland, BaltimoreInventors: Laure Aurelian, Cynthia Smith
-
Patent number: 5965357Abstract: A multiply-displayed peptide structure is provided for the serodiagnosis of HSV-2 antibodies, preferably by ELISA. The structure has the formula (1)): [(X.sup.1).sub.p --16aa sequence--(X.sup.2).sub.q --Sp].sub.n --core, wherein "16aa sequence" represents a sequence (SEQ ID NO: 68) Glu Glu Phe Glu Gly Ala Gly Asp Gly Glu Pro Pro 1 5 10 Glu Asp Asp Asp 15X.sup.1 and X.sup.2 which may be the same or different represent from 1 to 6 non-interfering amino acid residues, which may be the same or different;Sp represents a spacer group extending outwardly from the core;n is at least 4;p is 0 or 1;q is 0 or 1;and the linkage between the core and the spacer group may be chemical or physical.Preferably p is 1, q is 1, X.sup.1 is Pro, n is 4, and the core is a branched lysine core, whereby the whole structure is a peptide. The monomeric peptides (X.sup.1).sub.p --16aa sequence--(X.sup.2).sub.q --(Sp).sub.r, where r is 0 or 1 and their functional derivatives are useful intermediates in preparing the above structures.Type: GrantFiled: February 2, 1998Date of Patent: October 12, 1999Assignee: Medical Research CouncilInventor: Howard Sinkinson Marsden
-
Patent number: 5965354Abstract: Novel methods and immunodiagnostic test kits for diagnosing herpes simplex virus (HSV) infection are disclosed. The methods and kits employ both type-specific and type-common antigens, in a single-step assay format, to provide for highly accurate results. The methods discriminate between HSV-1 and HSV-2 infection so that an accurate diagnosis can be performed.Type: GrantFiled: March 8, 1996Date of Patent: October 12, 1999Assignee: Chiron CorporationInventors: Rae Lyn Burke, D'Anna Alexander
-
Patent number: 5965379Abstract: The present invention relates to methods for measuring endogenous cytokines in blood. The method accurately measures the cytokines in the blood in the presence of substances that bind the cytokines thereby causing the measurement of the cytokines by conventional methods to give inaccurate results. The present invention also includes the non-invasive measurement of cytokines in biological fluids such as saliva and nasal secretions. Finally, the present invention allows one to monitor the level of cytokines in the blood during treatment of a human or animal with cytokines.Type: GrantFiled: October 28, 1997Date of Patent: October 12, 1999Assignee: CytImmune Sciences Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Patent number: 5965375Abstract: This invention provides methods, compositions, and kits for detecting the presence of toxigenic strains of C. difficile in a biological sample. One embodiment provides methods for C. difficile detection that involve assaying for both C. difficile glutamate dehydrogenase and C. difficile toxin A or toxin B. In another embodiment, the invention provides a highly sensitive assay for C. difficile toxin A that is useful for determining whether a C. difficile strain is toxigenic. This embodiment involves binding of toxin A to a moiety that reversibly binds to a capture moiety present on a magnetic bead. A magnetic field is applied to the sample to concentrate the toxin A, after which the magnetic beads are dissociated and removed from the solution to obtain a highly concentrated preparation of toxin A, thus making possible a very sensitive assay.Type: GrantFiled: April 4, 1997Date of Patent: October 12, 1999Assignee: Biosite DiagnosticsInventor: Gunars E. Valkirs
-
Patent number: 5962236Abstract: Urinary assay for measuring bone resorption, by contacting an unhydrolyzed urine sample with an antibody that binds to free lysyl pyridinoline cross-links, detecting any binding of the antibody in the body fluid sample, and correlating the detected binding to bone resorption in vivo. The free lysyl pyridinoline cross-links are preferably measured as a ratio to the creatinine content in order to provide a urinary index of bone resorption independent of urine volume.Type: GrantFiled: December 11, 1998Date of Patent: October 5, 1999Assignee: Washington Research FoundationInventor: David R. Eyre
-
Patent number: 5962234Abstract: An in vitro method of identifying or isolating fetal cells from a blood sample is described. Fetal nucleated erythrocytes or erythroblasts are identified by using an antibody or antibody fragment specific for embryonic hemoglobin or an embryonic hemoglobin chain. Once the fetal cells are identified, they can be treated to render the fetal nucleic acids or proteins available for identification or amplification. Detecting the occurrence or existence of selected fetal nucleic acids or proteins allows a quantitative or qualitative diagnostic or prenatal evaluation, including determining the sex of the fetus, determining chromosomal, single gene or protein abnormalities, and determining the presence or absence of particular genes, nucleic acid sequences or proteins.Type: GrantFiled: September 25, 1998Date of Patent: October 5, 1999Assignee: Applied Imaging CorporationInventor: Mitchell Golbus
-
Patent number: 5962242Abstract: Diagnostic/prognostic methods are provided for screening for pathologies wherein an alteration in estrogen metabolism is indicative of a pathology or a susceptibility thereto which comprise detecting and/or quantifying directly in tissues and body fluids of mammals abnormal levels of estrone metabolites and their glucuronide conjugates. Particularly preferred methods involve the use of the 16OHE1-glucuronide fraction, i.e., the fraction which contains 16.alpha.-hydroxyestrone (16OHE1) and its conjugates, 16OHE1-3-glucuronide. Methods of preparing reagents to detect said 16OHE1-glucuronide fraction in tissues and body fluids are disclosed as well as test kits for performing the disclosed assays.Type: GrantFiled: August 22, 1997Date of Patent: October 5, 1999Assignee: Immuna Care CorporationInventor: Thomas L. Klug
-
Patent number: 5958715Abstract: Method of quantitative analysis of an enzyme linked immuno assay comprising the steps of forming an antigen--antibody complex between an antigen present in a sample to be tested and an enzyme labelled antibody and thereafter adding a substrate composition which can be converted into a differently colored product composition by the catalytic action of the enzyme. Quantification is achieved by measuring the time elapsed from addition of the substrate composition until a sudden color change discernible to the eye occurs. The measured time is then compared against a predetermined standard to determine the amount of antigen present in the sample.Type: GrantFiled: December 23, 1997Date of Patent: September 28, 1999Assignee: BRF InternationalInventor: Robert Edwin Muller
-
Patent number: 5955377Abstract: Method for detecting an analyte of interest, comprising the steps of providing a detection device comprising a light reflective or transmissive substrate supporting one or more layers comprising an adhering attachment layer to which is affixed a receptive material which specifically interacts with the analyte of interest; reacting the device with a sample potentially comprising the analyte under conditions in which the analyte binds to the receptive material; and reacting bound analyte with a reagent which creates a mass change on the surface of the device.Type: GrantFiled: April 17, 1995Date of Patent: September 21, 1999Assignee: Biostar, Inc.Inventors: Diana M. Maul, Gregory R. Bogart
-
Patent number: 5955289Abstract: In vivo and in vitro assays for the detection and quantification of substances, which are carcinogenic, but not genotoxic or mutagenic, by measuring a correlative change in cyclin dependent kinases (CDK).Type: GrantFiled: March 7, 1995Date of Patent: September 21, 1999Assignee: Brown, Pinnisi & Michaels, PCInventors: Xinfang Ma, Joseph A. Rininger, Brian E. Johnson, Debra S. Whiting
-
Patent number: 5952186Abstract: A first embodiment of the method is for analyzing the amount of methionine sulfoxide in a protein sample and includes the steps of contacting a protein solution with methionine sulfoxide reductase in the presence of a reducing reagent bearing a covalently-linked reporter tag, whereby the reducing reagent is oxidized. The oxidized reducing reagent formed, which is in proportion to the amount of methionine sulfoxide in the sample, is then quantified. A second embodiment of the method is for analyzing the amount of disulfide linkages in a polypeptide or protein sample. It proceeds in the same fashion as above, but in the absence of any enzyme. A novel fluorescently-labeled reducing agent, and kits to practice the method are also disclosed.Type: GrantFiled: April 16, 1996Date of Patent: September 14, 1999Assignee: Promega CorporationInventors: John Shultz, Susanne Selman, Daniel J. Simpson
-
Patent number: 5952173Abstract: The present invention relates to analytical devices for determining the presence or amount of an analyte in a test sample. The analytical devices comprise an inlet port, a vent, a channel, and an array of structures. The structures have immobilized reagent covalently or non-covalently attached to the surface of the structures. The immobilized reagent captures analyte in the test sample where it is detected by a detection system. The present invention also provides methods and reagents for performing assays utilizing the analytical devices of the present invention. The present invention also provides methods of manufacturing the analytical devices of the present invention.Type: GrantFiled: August 21, 1997Date of Patent: September 14, 1999Assignee: Abbott LaboratoriesInventors: Douglas D. Hansmann, John P. Grace, Michael G. Lowery, Gary M. Oosta, Neil W. Loomis, Eric B. Shain, Thomas G. Schapira
-
Patent number: 5948629Abstract: Receptors for the zonula occludens toxin of Vibrio cholera, as well as methods involving the use of the same are disclosed.Type: GrantFiled: November 5, 1998Date of Patent: September 7, 1999Assignee: University of Maryland at BaltimoreInventor: Alessio Fasano
-
Patent number: 5945294Abstract: The present invention includes a method to detect IgE using a human Fc epsilon receptor (Fc.sub..epsilon. R) to detect IgE antibodies in a biological sample from a cat, a dog, or a horse. The present invention also relates to kits to perform such methods.Type: GrantFiled: November 26, 1996Date of Patent: August 31, 1999Assignee: Heska CorporationInventors: Glenn R. Frank, James P. Porter, Keith E. Rushlow, Donald L. Wassom
-
Patent number: 5939331Abstract: A method and device for detecting the presence, absence or amount of an analyte in a whole blood sample is disclosed. The device comprises four zones, a sample receiving zone, a labeling zone, a capture zone and an absorbent zone. The sample receiving zone contains an irreversibly immobilized reagent that allows for removal of substantially all red blood cells from the whole blood sample. Flow through the device is via capillary migration and all of the dissolved or dispersed components in the sample flow at substantially equal rates and with relatively unimpaired flow through the device. The method involves the use of the device for detection of analyte in a whole blood sample.Type: GrantFiled: May 21, 1993Date of Patent: August 17, 1999Assignee: Quidel CorporationInventors: John Burd, Steven Miller, Gerald Rowley, Allan Pronovost
-
Patent number: 5939257Abstract: Enzymatically active thermostable alkaline phosphatases from Rhodothermus marinus, Thermus thermophilus, and Thermosipho africanus.Type: GrantFiled: October 25, 1996Date of Patent: August 17, 1999Assignee: Amersham Life Science, Inc.Inventors: Joseph Szasz, Maria Davis
-
Patent number: 5939272Abstract: Assay methods for performing non-competitive ligand-receptor assays, where said assays provide a sensible result when the target ligand identified by the assay is present at a concentration greater than a defined threshold concentration. The threshold concentration can be selected to be the upper limit of a normal range of values for a target ligand in a sample, so that an assay in accordance with the invention provides a sensible result only when the target ligand is present at elevated levels.Type: GrantFiled: June 11, 1997Date of Patent: August 17, 1999Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Gunars E. Valkirs, Richard R. Anderson
-
Patent number: 5935801Abstract: A monoclonal antibody which specifically binds to an antigen on the membrane of mitochondria in apoptotic cells. The antigen is a 38 kD protein that is detectable in cells undergoing apoptosis and undetectable in normal cells. This selectivity of the monoclonal antibody provides a method of distinguishing between normal and apoptotic cells in a sample of human hemopoietic cell populations. A method for detecting and measuring cells undergoing apoptosis is also provided.Type: GrantFiled: March 29, 1996Date of Patent: August 10, 1999Assignee: Dana-Farber Cancer InstituteInventors: Stuart Franklin Schlossman, Chonghui Zhang
-
Patent number: 5935780Abstract: For the qualitative or/and quantitative detection of a substance to be determined in a test sample with the aid of an immunoassay or nucleic acid hybridization assay the following components are used:a) a capture reagent which enables a specific detection of the substance to be determined by means of two different binding sites 1) if desired together with further test components and 2) is bound or is capable of binding to an active solid phase via a specific binding pair one partner of which is linked to the capture reagent and the second partner of which is coupled to an active solid phaseb) an active solid phase andc) an inactive solid phase which substantially corresponds to the active solid phase but to which the capture reagent cannot bind,wherein the test sample is either firstly brought into contact with the inactive solid phase alone and only later with the active solid phase, or is simultaneously brought into contact with the active and inactive solid phase during which the capture reagent and if desType: GrantFiled: September 21, 1995Date of Patent: August 10, 1999Assignee: Boehringer Mannheim GmbHInventor: Werner Naser
-
Patent number: 5932480Abstract: A sample containing hemoglobin A1c (HbA1c) is simultaneously brought in contact with a solid phase and anti-HbA1c antibody, the anti-HbA1c antibody bound to the adsorbed HbA1c on the solid phase and the anti-HbA1c antibody in solution are separated, and the anti-HbA1c antibody bound to the adsorbed HbA1c on the solid phase is detected. HbA1c % is determined by one-step immunoassay, and the time required for measurement is shortened in comparison with conventional immunoassay methods. Since the exposure time to the pretreatment solution present in the reaction solution during the immune reaction is shortened, formation of a precipitate in the sample as well as inactivation of the enzyme of the enzyme-labeled anti-HbA1c antibody, when used, is reduced.Type: GrantFiled: March 13, 1997Date of Patent: August 3, 1999Assignee: Tosoh CorporationInventors: Naoko Maruo, Masuo Inoue
-
Patent number: 5932431Abstract: A method and kit for measurement of a steroid by means of a competitive immunoassay, preferably a competitive enzyme immunoassay. The method and kit involve the use of a steroid analogue conjugated to a label. The steroids that are amenable to detection by the method and kit of the present invention include estradiol and progesterone. The method comprises the steps of:a. incubating a mixture of a test sample suspected of containing a given steroid, a solid phase coupled to an antibody specific for that steroid, and a conjugate of an analogue of that steroid to form steroid/antibody complexes and conjugate/antibody complexes on said solid phase;b. separating said solid phase from said mixture;c. measuring the amount of label present in said mixture or in said solid phase; andd. determining the amount of steroid in said sample from the amount of label. The kit comprises a solid phase coupled to an antibody specific for a steroid and a conjugate of an analogue of that steroid.Type: GrantFiled: April 16, 1997Date of Patent: August 3, 1999Assignee: Abbott LaboratoriesInventors: Gregg T. Williams, William R. Groskopf, Harold N. Baker, Dalmacio A. Agdeppa
-
Patent number: 5928886Abstract: The present invention relates to a dry immunoassay analytical element for assaying a ligand, comprising a support bearing: (a) a label zone comprising an enzyme labeled ligand or an enzyme labeled receptor; (b) a spreading zone; (c) a receptor zone comprising a fixed concentration of an immobilized receptor for the ligand; and (d) a gravure zone comprising a diaryl telluride. A prefered embodiment of the present invention further comprises a vanadyl salt. The present invention further relates to a method for performing an assay using an element as described above.Type: GrantFiled: September 23, 1997Date of Patent: July 27, 1999Assignee: Johnson & Johnson Clinical Diagnostics, Inc.Inventors: Margaret Elizabeth Logan, Janet Fyles, Stephen Hasselberg
-
Patent number: 5928873Abstract: In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.Type: GrantFiled: March 23, 1998Date of Patent: July 27, 1999Assignee: Thomas Jefferson UniversityInventor: Scott A. Waldman
-
Patent number: 5925532Abstract: The subject invention provides an antibody which specifically binds to the product of a reaction between a labeling substance and a substrate. The subject invention also provides a method of making an immunogen used to produce the antibody of the subject invention. The invention further provides methods of using the subject antibody for detecting an antigen of interest in a sample, for example, detecting a protein comprising an amino acid sequence of interest and detecting a nucleic acid molecule comprising a nucleic acid sequence of interest, detecting a polypeptide such as those expressed by infectious agents, fungi or parasites.Type: GrantFiled: July 22, 1997Date of Patent: July 20, 1999Assignee: The Trustees of Columbia University in the City of New YorkInventors: Bernard F. Erlanger, Bi-Xing Chen
-
Patent number: 5925526Abstract: An isolated nucleic acid sequence encoding major Yo paraneoplastic antigenic polypeptide is provided by this invention. This invention also provides a purified major Yo antigenic polypeptide and compositions containing the purified major Yo antigenic polypeptide. Further provided by this invention is a monoclonal antibody directed to an epitope on the major Yo paraneoplastic antigenic polypeptide. Compositions containing this monoclonal antibody also are provided by this invention. This invention also provides methods of diagnosis and treatment using the compositions described hereinabove.Type: GrantFiled: June 7, 1995Date of Patent: July 20, 1999Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Jerome B. Posner, Henry M. Furneaux
-
Patent number: 5919642Abstract: Simplified calibration and improved dose-response linearity of the standard curve of competitive assays are obtained by adding a predetermined amount of unlabeled competitive binding compound (usually just the analyte itself) to a first reagent containing anti-analyte antibodies before the reagent is reacted with a sample containing an unknown amount of analyte.Type: GrantFiled: October 8, 1997Date of Patent: July 6, 1999Assignee: Boehringer Mannheim CorporationInventors: Pyare Khanna, William A. Coty, Dean Jenkins